Market revenue in 2023 | USD 379.9 million |
Market revenue in 2030 | USD 604.4 million |
Growth rate | 6.9% (CAGR from 2023 to 2030) |
Largest segment | Hereditary non-cancer testing |
Fastest growing segment | Hereditary Cancer Testing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hereditary Cancer Testing, Hereditary Non-cancer Testing |
Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Illumina Inc, Natera Inc, Labcorp Holdings Inc, Roche Holding AG ADR, Quest Diagnostics Inc, CooperSurgical, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Twist Bioscience Corp, Sophia Genetics SA, Fulgent Genetics Inc, MedGenome, Centogene NV Ordinary Shares, The Cooper Companies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary testing market will help companies and investors design strategic landscapes.
Hereditary non-cancer testing was the largest segment with a revenue share of 81.78% in 2023. Horizon Databook has segmented the France hereditary testing market based on hereditary cancer testing, hereditary non-cancer testing covering the revenue growth of each sub-segment from 2018 to 2030.
In France, the National Health Care System covers access to cancer genetic testing and services. The French Ministry of Health together with French National Cancer Institute developed Cancer Plan, 2009– 2013, which incorporated information on hereditary predisposition to cancers. National Cancer Institute funds the French genetic counseling units and genetic laboratories.
Apart from this, the French Genetic and Cancer Group (GGC) provides guidelines for multigene panel analysis of hereditary ovarian and breast cancer predisposition. Therefore, well-established, and supportive regulatory framework that promotes hereditary testing for inherited cancers is expected to boost adoption of testing solutions in France.
According to International Cancer Genome Consortium (ICGC), there are nearly 70,000 new cases of prostate cancer diagnosed reported annually and around 8,700 males die from this disease. The high prevalence of prostate cancer creates an equally significant demand for hereditary testing solutions in France.
Horizon Databook provides a detailed overview of country-level data and insights on the France hereditary testing market, including forecasts for subscribers. This country databook contains high-level insights into France hereditary testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account